Top

Published in:

Open Access 01-12-2016 | Research article

Single-cell antibody nanowells: a novel technology in detecting anti-SSA/Ro60- and anti-SSB/La autoantibody-producing cells in peripheral blood of rheumatic disease patients

Authors: Lida Esfandiary, Nirupama Gupta, Alexandria Voigt, Arun Wanchoo, Edward K. L. Chan, Sukesh Sukumaran, Cuong Q. Nguyen

Published in: Arthritis Research & Therapy | Issue 1/2016

Abstract

Background

Anti-SSA/Ro60 and anti-SSB/La are essential serological biomarkers for rheumatic diseases, specifically Sjögren’s syndrome (SS) and systemic lupus erythematosus (SLE). Currently, laboratory detection technology and platforms are designed with an emphasis on high-throughput methodology; therefore, the relationship of sensitivity with specificity remains a significant area for improvement. In this study, we used single-cell antibody nanowells (SCAN) technology to directly profile individual B cells producing antibodies against specific autoantigens such as SSA/Ro60 and SSB/La.

Methods

Peripheral blood mononuclear cells were isolated using Ficoll gradient. Fluorescently labeled cells were added to fabricated nanowells and imaged using a high-speed epifluorescence microscope. The microengraving process was conducted using printed slides coated with immunoglobulins. Printed slides were hybridized with fluorescence-conjugated immunoglobulin G (IgG), SSA/Ro60, and SSB/La antigens. Microarray spots were analyzed for nanowells with single live B cells that produced antigen-specific autoantibodies.

Results

Our results indicate that SCAN can simultaneously detect high frequencies of anti-SSA/Ro60 and anti-SSB/La with a specific IgG isotype in peripheral blood mononuclear cells of patients, as well as measure their individual secretion levels. The data showed that patients with SS and SLE exhibited higher frequency and greater concentration of anti-SSA/Ro60- and anti-SSB/La-producing B cells in the IgG isotype. Furthermore, individual B cells of patients produced higher levels of IgG-specific anti-SSA/Ro60 autoantibody, but not IgG-specific anti-SSB/La autoantibody, compared with healthy control subjects.

Conclusions

These results support the application of SCAN as a robust multiparametric analytical bioassay that can directly measure secretion of autoantibody and accurately report antigen-specific, autoantibody-producing cells.

Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjögren’s syndrome. Scand J Rheumatol. 2000;29(6):341–8.CrossRefPubMed

Cornec D, Jamin C, Pers JO. Sjögren’s syndrome: where do we stand, and where shall we go? J Autoimmun. 2014;51:109–14.CrossRefPubMed

Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjögren’s syndrome: where are we, and where are we going? Arthritis Rheum. 2005;52(10):2984–95.CrossRefPubMed

Dawson LJ, Fox PC, Smith PM. Sjögrens syndrome—the non-apoptotic model of glandular hypofunction. Rheumatology (Oxford). 2006;45(7):792–8.CrossRef

Sawalha AH, Harley JB. Antinuclear autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol. 2004;16(5):534–40.CrossRefPubMed

Harley JB, Alexander EL, Bias WB, Fox OF, Provost TT, Reichlin M, et al. Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren’s syndrome. Arthritis Rheum. 1986;29(2):196–206.CrossRefPubMed

Routsias JG, Tzioufas AG. Sjögren’s syndrome—study of autoantigens and autoantibodies. Clin Rev Allergy Immunol. 2007;32(3):238–51.CrossRefPubMed

Jonsson R, Theander E, Sjöström B, Brokstad K, Henriksson G. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA. 2013;310(17):1854–5.CrossRefPubMed

Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G. Prediction of Sjögren’s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol. 2015;67(9):2427–36.CrossRefPubMed

10.

Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64(7):2319–27.CrossRefPubMedPubMedCentral

11.

Halse A, Harley JB, Kroneld U, Jonsson R. Ro/SS-A-reactive B lymphocytes in salivary glands and peripheral blood of patients with Sjögren’s syndrome. Clin Exp Immunol. 1999;115(1):203–7.CrossRefPubMedPubMedCentral

12.

Maier-Moore JS, Koelsch KA, Smith K, Lessard CJ, Radfar L, Lewis D, et al. Antibody-secreting cell specificity in labial salivary glands reflects the clinical presentation and serology in patients with Sjögren’s syndrome. Arthritis Rheumatol. 2014;66(12):3445–56.CrossRefPubMedPubMedCentral

13.

Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53(6):424–32.CrossRefPubMedPubMedCentral

14.

Hanly JG, Su L, Farewell V, Fritzler MJ. Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. J Immunol Methods. 2010;358(1-2):75–80.CrossRefPubMed

15.

Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014;2014:315179.PubMedPubMedCentral

16.

Satoh M, Tanaka S, Chan EK. The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases. Front Immunol. 2015;6:181.CrossRefPubMedPubMedCentral

17.

Nguyen CQ, Ogunniyi AO, Karabiyik A, Love JC. Single-cell analysis reveals isotype-specific autoreactive B cell repertoires in Sjögren’s syndrome. PLoS One. 2013;8(3), e58127.CrossRefPubMedPubMedCentral

18.

Ogunniyi AO, Story CM, Papa E, Guillen E, Love JC. Screening individual hybridomas by microengraving to discover monoclonal antibodies. Nat Protoc. 2009;4(5):767–82.CrossRefPubMedPubMedCentral

19.

Story CM, Papa E, Hu CC, Ronan JL, Herlihy K, Ploegh HL, et al. Profiling antibody responses by multiparametric analysis of primary B cells. Proc Natl Acad Sci U S A. 2008;105(46):17902–7.CrossRefPubMedPubMedCentral

20.

Billaut-Mulot O, Cocude C, Kolesnitchenko V, Truong MJ, Chan EK, Hachula E, et al. SS-56, A novel cellular target of autoantibody responses in Sjögren syndrome and systemic lupus erythematosus. J Clin Invest. 2001;108(6):861–9.CrossRefPubMedPubMedCentral

21.

Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun. 2012;39(1-2):15–26.CrossRefPubMed

22.

Gordon TP, Bolstad AI, Rischmueller M, Jonsson R, Waterman SA. Autoantibodies in primary Sjögren’s syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity. 2001;34(2):123–32.CrossRefPubMed

23.

Tzioufas AG, Wassmuth R, Dafni UG, Guialis A, Haga HJ, Isenberg DA, et al. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren’s syndrome (pSS): a European multicentre study. Ann Rheum Dis. 2002;61(5):398–404.CrossRefPubMedPubMedCentral

24.

Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: from diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev. 2015;14(6):555–63.CrossRefPubMed

25.

Halse A, Wahren-Herlenius M, Jonsson R. Ro/SS-A- and La/SS-B-reactive B lymphocytes in peripheral blood of patients with Sjögren’s syndrome. Clin Exp Immunol. 1999;115(1):208–13.CrossRefPubMedPubMedCentral

26.

Hu S, Vissink A, Arellano M, Roozendaal C, Zhou H, Kallenberg CG, et al. Identification of autoantibody biomarkers for primary Sjögren’s syndrome using protein microarrays. Proteomics. 2011;11(8):1499–507.CrossRefPubMedPubMedCentral

27.

Volchenkov R, Jonsson R, Appel S. Anti-Ro and anti-La autoantibody profiling in Norwegian patients with primary Sjögren’s syndrome using luciferase immunoprecipitation systems (LIPS). Scand J Rheumatol. 2012;41(4):314–5.CrossRefPubMed

28.

Satoh M, Chan EK, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol. 2007;3(5):721–38.CrossRefPubMed

Title: Single-cell antibody nanowells: a novel technology in detecting anti-SSA/Ro60- and anti-SSB/La autoantibody-producing cells in peripheral blood of rheumatic disease patients
Authors: Lida Esfandiary
Nirupama Gupta
Alexandria Voigt
Arun Wanchoo
Edward K. L. Chan
Sukesh Sukumaran
Cuong Q. Nguyen
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 1/2016
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/s13075-016-1010-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Single-cell antibody nanowells: a novel technology in detecting anti-SSA/Ro60- and anti-SSB/La autoantibody-producing cells in peripheral blood of rheumatic disease patients

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis

A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls

The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritis

PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus

A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease

Erratum to: Concentration of antibodies against Porphyromonas gingivalisis increased before the onset of symptoms of rheumatoid arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page